Elderly aggressive-histology non-Hodgkin's lymphoma: First-line VNCOP-B regimen experience on 350 patients

Blood

Volumn 94, Issue 1, 1999, Pages 33-38

  Zinzani, Pier Luigi ^a   Storti, Sergio ^b   Zaccaria, Alfonso ^b   Moretti, Luciano ^b   Magagnoli, Massimo ^b   Pavone, Enzo ^b   Gentilini, Patrizia ^b   Guardigni, Luciano ^b   Gobbi, Marco ^b   Fattori, Pier Paolo ^b   Falini, Brunangelo ^b   Lauta, Vito Michele ^b   Bendandi, Maurizio ^b   Gherlinzoni, Filippo ^b   De Renzo, Amalia ^b   Zaja, Francesco ^b   Mazza, Patrizio ^b   Volpe, Ettore ^b   Bocchia, Monica ^b   Aitini, Enrico ^b   Tabanelli, Maurizio ^b   Leone, Giuseppe ^b   Tura, Sante ^b   more..

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; METHOTREXATE; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER REGRESSION; CANCER SURVIVAL; FEMALE; GERIATRIC PATIENT; HISTOPATHOLOGY; HUMAN; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COHORT STUDIES; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MITOXANTRONE; PREDNISONE; REMISSION INDUCTION; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 0033168330     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Devesa SS, Fears T: Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Res 52:5432, 1992
2. Morgan GJ, Jack A, Clayden AD, Brincker H, Coebergh JW, Carli PM, Vornanen M, Tumino R, Cartwright RC: Trends in the incidence of lymphoma in Europe. Br J Haematol 93:104, 1996 (suppl 2, abstr 406)
3. National Cancer Institute, Cancer Statistics Review, 1973-1988. NIH publication 91-2789. Bethesda, MD, National Cancer Institute, 1991
4. Mazza P, Zinzani PL, Martelli M, Fiacchini M, Bocchia M, Pileri S, Falini B, Martelli MF, Amadori S, Papa G, Cantonetti M, Lucarelli G, Moretti L, Calabresi F, Ruggeri E, Gherlinzoni F, Bendandi M, Guglielmi C, Burgio V, Dammacco F, Lauta VM, Liberati AM, Mandelli F, Tura S: MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas. Leuk Lymphoma 16:457, 1995
5. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA, Miller TP: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002, 1993
6. The International non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987, 1993
7. Bessel EM, Coutts A, Fletcher J, Toghill PJ, Moloney AJ, Ellis IO, Hulman G, Jenkins D: Non-Hodgkin's lymphoma in elderly patients: A phase II study of MCOP chemotherapy in patients aged 70 years or over with intermediate or high-grade histology. Eur J Cancer 30A: 1337, 1994
8. Gloeckler Ries L, Pollack ES, Young JL Jr: Cancer patient survival: Surveillance, epidemiology, and end results program, 1973-79. J Natl Cancer Inst 70:639, 1983
9. Armitage JO, Potter JF: Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly. Increased complications with advancing age. J Am Geriatr Soc 32:269, 1984
10. Novitzky N, King HS, Johnson C, Jacobs P: Treatment of aggressive non-Hodgkin's lymphoma in the elderly. Am J Hematol 49:103, 1995
11. Chubachi A, Miura AB, Takatsu H, Yamaguchi H, Nishimura S, Nakayama Y, Akihama T, Miura A, Saitoh M, Watanuki T: A retrospective comparison of old and young patients with non-Hodgkin's lymphoma. Rinsho Ketsueki 33:303, 1992
12. Grogan L, Corbally N, Dervan PA, Byrne A, Carney DN: Comparable prognostic factors and survival in elderly patients with aggressive non-Hodgkin's lymphoma treated with standard-dose Adriamycin-based regimens. Ann Oncol 5:47, 1994
13. O'Connell MJ, Earle JD, Harrington DP, Johnson GJ, Glick JH: Initial chemotherapy doses for elderly patients with malignant lymphoma. J Clin Oncol 4:1418, 1986
14. Sonneveld P, Michiels JJ: Full-dose chemotherapy in elderly patients with non-Hodgkin's lymphoma. A feasibility study using a mitoxantrone-containing regimen. Br J Cancer 62:105, 1990
15. Tirelli U, Zagonel V, Errante D, Serraino D, Talamini R, De Cicco M, Carbone A, Monfardini S: A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma. J Clin Oncol 10:228, 1992
16. Salvagno L, Contu A, Bianco A: A combination of mitoxantrone, etoposide and prednisone in elderly patients with non-Hodgkin's lymphoma. Ann Oncol 3:833, 1992
17. O'Reilly SE, Klimo P, Connors JM: Low-dose ACOP-B and VABE. Weekly chemotherapy for elderly patients with advanced-stage diffuse large-cell lymphoma. J Clin Oncol 9:741, 1991
18. O'Reilly SE, Connors JM, Howdle S, Hoskins P, Klasa R, Klimo P, Stuart DS: In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma. J Clin Oncol 11:2250, 1993
19. Ansell SM: A phase II trial of chemotherapy combination in elderly patients with aggressive lymphoma. Ann Oncol 4:172, 1993
20. Tirelli U, Carbone A, Zagonel V, Veronesi A, Canetta R: Non-Hodgkin's lymphoma in the elderly: Prospective studies with specifically devised chemotherapy regimens in 66 patients. Eur J Cancer Clin Oncol 23:535, 1987
21. McMaster ML, Johnson DH, Greer JP, Wolff SN, Hildreth CR, Greco FA, Hainsworth JD: A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma. Cancer 67:1487, 1991
22. Martelli M, Guglielmi C, Coluzzi S, Avvisati G, Amadori S, Giovannini M, Torromeo C, Mandelli F: P-VABEC: A prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma. J Clin Oncol 11:2362, 1993
23. Bastion Y, Blay JY, Divine M, Brice M, Bordessoule, Sebban C, Blanc M, Tilly H, Lederlin P, Deconinck E, Salles B, Dumontet C, Briere J, Coiffier B: Elderly patients with aggressive non-Hodgkin's lymphoma: Disease presentation, response to treatment, and survival - A Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J Clin Oncol 15:2945, 1997
24. Herait P, Poutignat N, Marty M: Early assessment of a new anticancer drug analogue. Are the historical comparisons obsolete? The French experience with pirarubicin. Eur J Cancer 28:1670, 1992
25. Temma K, Akera T, Chugun A: Comparison of cardiac actions of doxorubicin pirarubicin and aclarubicin in isolated guinea-pig heart. Eur J Pharmacol 234:173, 1993
26. Bosly A, Lepage E, Coiffier B, Dupriez B, Herbrecht R, Fillet G, Divine M, Nouvel C, Tilly H, Bourdessoule D, Gaulard P, Gisselbrecht C: In elderly patients with non-Hodgkin's lymphoma, alternance of chemotherapy is not superior to ACVB + consolidation: A prospective randomized study on 884 patients. LNH87 protocol group 3: A GELA study (abstract 207). Ann Oncol 7:60, 1996
27. Zinzani PL, Bendandi M, Gherlinzoni F, Mazza P, Salvucci M, Aitini E, Miggiano MC, Gozzetti A, Tura S: VNCOP-B regimen in the treatment of high-grade non-Hodgkin's lymphoma in the elderly Haematologica 78:378, 1993
28. Zinzani PL, Pavone E, Storti S, Moretti L, Fattori PP, Guardigni L, Falini B, Gobbi M, Gentilini P, Lauta VM, Bendandi M, Gherlinzoni F, Magagnoli M, Venturi S, Aitini E, Tabanelli M, Leone G, Liso V, Tura S: Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 89:3974, 1997
29. Stansfeld A, Diebold J, Kapanci Y, Kelenyi G, Lennert K, Mioduszewska O, Noel H, Rilke F, Sundstrom C, van Unnik JAM, Wright DH: Updated Kiel classification for lymphoma. Lancet 1:292, 1988
30. Carbone PP, Kaplan HS, Musshoff K: Report of the Committee on Hodgkin's Disease Staging Classifications. Cancer Res 31:1860, 1971
31. Oken M, Creech R, Tormey D: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649, 1982
32. Klimo P, Connors JM: MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 102:596, 1985
33. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
34. Cox DR: Regression models and life tables (with discussion). J R Stat Soc B 34:187, 1972
35. Dixon DO, Neilan B, Jones SE, Lipschtz DA, Miller TP, Grozea PN, Wilson HE: Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience. J Clin Oncol 4:295, 1986
36. Meyer RM, Browman GP, Samosh ML, Benger AM, Bryant-Lukosius D, Wilson EC, Frank GL, Leber BF, Sternbach MS, Foster GA, Skingley P, Levine MN: Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol 13:2386, 1995
37. Sonneveld P, de Ridder M, van der Lelie H, Nieuwenhuis K, Schouten H, Mulder A, van Reijswoud I, Hop W, Lowenberg B: Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 13:2530, 1995
38. Tirelli U, Errante D, Van Glabbeke M, Teodorovic I, Kluin-Nelemans JC, Thomas J, Bron D, Rosti G, Sorners R, Zagonel V, Noordijk EM: CHOP is the standard regimen in patients ≥70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: Results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 16:27, 1998
39. Bertini M, Freilone R, Vitolo U, Botto B, Pizzuti M, Gavarotti P, Levis A, Orlandi E, Orsucci L, Pini M, Rota Scalabrini D, Salvi F, Seconde V, Todeschini G, Viero P, Volta C, Resegotti L: P-VEBEC: A new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL). Ann Oncol 5:895, 1994
40. Zagonel V, Babare R, Merola MC, Talamini R, Lazzarini R, Tirelli U, Carbone A, Monfardini S: Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy. Ann Oncol 5:127, 1994
41. Gomez H, Mas L, Casanova L, Kay Pen DL, Santillana S, Valdivia S, Otero J, Rodriguez W, Carracedo C, Vallejos C: Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: Identification of two age subgroups with differing hematologic toxicity. J Clin Oncol 16:2352, 1998